As a biologist, I scrutinized this presentation. Once again, the presented data are incontrovertible, at this early research stage in murine (mouse) subjects. 2-73 clearly treats the cellular symptoms of Alzheimer’s (Tau tangles, A-beta accumulations), resulting in restored and normalized behavioral functions.
Importantly, the Alzheimer’s disease conditions were chemically and genetically induced in the mice, to thereafter discern 2-73's efficacy. This murine model of Alzheimer’s is exactly parallel to the conditions in human Alzheimer’s cells ---- where I fully expect equivalent efficacy.
2-73 was administered in the drinking water of the mice, not by injection. This oral administration was effective, without any noted side effects or adverse outcomes. This indicates that 2-73 is able to be effectively absorbed without digestion or premature ejection, and even more importantly, it is able to independantly cross the blood/brain barrier and be sufficiently absorbed by neurons. This favorable constellation of traits is exceptionally rare, and without the detailed lab work on the mice described in the presentation, would not be anticipated. Seemingly too good to be true. But the lab work authenticates the absorption observations. (The blood/brain barriers and cellular membranes of mice are essentially identical to human ones. There is no reason whatsoever to think these results will not occur in humans with Alzheimer’s.)
As I’ve posted before, Anavex 2-73 is not just “some other” new Alzheimer’s (and general neurodegenerative) treatment guess or gamble. Biochemically, it is in a class of its own. It works differently from conventional drugs, and it fixes the root cause of the majority of neurodegenerative diseases, the disconnection or malfunction of the mitochondrion-endoplasmic reticulum junction.
